FIRVANQ
Total Payments
$59,549
Transactions
22
Doctors
2
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $31,677 | 8 | 0 |
| 2019 | $2,933 | 6 | 1 |
| 2018 | $24,939 | 8 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $49,526 | 10 | 83.2% |
| Consulting Fee | $7,210 | 11 | 12.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,813 | 1 | 4.7% |
Payments by Type
Research
$49,526
10 transactions
General
$10,023
12 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Vancomycin for Primary Sclerosing Cholangitis | Azurity Pharmaceuticals, Inc. | $31,677 | 0 |
| In-vitro activity of vancomycin hydrochloride oral solutions (RM-01) compared to Sigma Aldrich vancomycin HCl standard against Clostridium difficile and Staphylococcus aureus | CutisPharma, Inc. | $17,849 | 0 |
Ad
Manufacturing Companies
- Azurity Pharmaceuticals, Inc. $31,677
- CutisPharma, Inc. $27,872
Product Information
- Type Drug
- Total Payments $59,549
- Total Doctors 2
- Transactions 22
About FIRVANQ
FIRVANQ is a drug associated with $59,549 in payments to 2 healthcare providers, recorded across 22 transactions in the CMS Open Payments database. The primary manufacturer is Azurity Pharmaceuticals, Inc..
Payment data is available from 2018 to 2020. In 2020, $31,677 was paid across 8 transactions to 0 doctors.
The most common payment nature for FIRVANQ is "Unspecified" ($49,526, 83.2% of total).
FIRVANQ is associated with 2 research studies, including "Vancomycin for Primary Sclerosing Cholangitis" ($31,677).